The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.
Percutaneous coronary intervention is the preferred revascularization approach for most patients with coronary artery disease. However, this strategy is limited by renarrowing of the vessel by neointimal hyperplasia within the stent lumen (in-stent restenosis). Vascular smooth muscle cell proliferation is a major component in this healing process. This process is mediated by multiple cytokines and growth factors, which share a common pathway in inducing cell proliferation: the cell cycle. The cell cycle is highly regulated by numerous mechanisms ensuring orderly and coordinated cell division. The present review discusses current concepts related to regulation of the cell cycle and new therapeutic options that target aspects of the cell cycle.
Charron
Thierry
T
Roy and Ann Foss International Cardiology Research Program, Terrence Donnelly Heart Centre, St Micheal's Hospital, University of Toronto, Ontario.
Nili
Nafiseh
N
Strauss
Bradley H
BH
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D003324:Coronary Artery Disease / Q000503:physiopathology / Q000628:therapy; D023903:Coronary Restenosis / Q000473:pathology / Q000503:physiopathology* / Q000517:prevention & control*; D015316:Genetic Therapy; D006801:Humans; D006965:Hyperplasia; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D017539:Tunica Intima / Q000473:pathology